Drugs / RTI-336
RTI-336
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00808119 | Oct 2008 → Mar 2009 | cocaine dependence | RTI International | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01601717 Comparator | Jan 2010 → Jan 2012 | amphetamine abuse, methamphetamine dependence | Baylor College of Medicine | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTI-336 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00808119 ↗ |
| Known as | CTDP 31862 | “RTI-336 (CTDP 31862)” NCT00808119 ↗ |
| Known as | RTI 4229-336 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1186581 ↗ |
| Action | Inhibit | “RTI-336 is a novel dopamine transporter inhibitor of the 3-phenyltropane class” NCT00808119 ↗ |
| Modality | Small molecule | — CHEMBL1186581 ↗ |
| Route | Oral | “following administration of single, oral doses” NCT00808119 ↗ |